Results 171 to 180 of about 497,459 (309)

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

The Effect of Hemolysis on Biochemical Tests: Determining Interference Cutoffs and Managing Hemolytic Samples. [PDF]

J Anal Methods Chem
Yeganeh BS, Soleimani N, Zare S, Mohammadzadeh S, Amiri F, Esmaeili MJ, Soleimani D, Khoshnyat S.   +7 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Infectious Serology in Total Laboratory Automation: Fit or Unfit. [PDF]

Cureus
Meena S.
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Louis Rosenfeld, Four centuries of clinical chemistry, Amsterdam, Gordon and Breach Science Publishers, 1999, pp. xvii, 562, illus., £91.00 (hardback 90-5699-645-2). [PDF]

, 2002
Lawrence, CJ
core  

Performance Analysis of Clinical Chemistry Laboratory Using Sigma Metrics in the Total Testing Process at Dessie Comprehensive Specialized Hospital, Ethiopia. [PDF]

J Clin Lab Anal
Mulatie Z, Ebrahim E, Alebachew M, Gedefie A, Eshetu B, Tilahun M, Debash H, Kassa Y, Alemayehu E, Gessese T.   +9 more
europepmc   +1 more source

Continuous-flow techniques for tests in clinical chemistry. [PDF]

Journal of Clinical Pathology, 1969
D W, Neill, J R, Doggart
openaire   +2 more sources

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

When cold complicates: the impact of cryoglobulins and pre-analytical conditions on monoclonal protein analysis. [PDF]

Clin Exp Med
Cunningham A, Rotteveel D, Scherrenburg J, Jacobs JFM, van Aggelen D, van Uum-Otters M, Vlot AJ, Verheggen R, Ruinemans-Koerts J, Oostendorp M.   +9 more
europepmc   +1 more source